Sign in
TerminatedNo phase

Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases

Key facts

Who runs it
Alpha Tau Medical LTD.
Where
Russia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
1 person enrolled
Started
28 Aug 2019
Ended
30 Nov 2023
Type of study
Interventional
Treatments tested
  • Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Record updated
18 January 2024
Why it stopped
Difficulty in recruiting patients

Who can take part

Age
45 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (28)Hide the full registry criteria

Who can take part

  • Subjects with histopathological confirmation of primary (or recurrent) invasive breast carcinoma and distant metastatic disease at diagnosis
  • Target tumor size ≤ 3.0 cm (T1-2b category)
  • Morphological type: invasive breast cancer
  • Luminal-type A (ER+, PR+, Her2/neu +1), HER+, luminal-type B (ER +/-, PR +/-, Her2/neu+1), or Triple negative breast carcinoma
  • Measurable disease according to RECIST v1.1
  • Subjects over 45 years old
  • Subjects' ECOG Performance Status Scale is < 2
  • Subjects' life expectancy more than 6 months
  • Platelet count ≥100,000/mm3
  • International normalized ratio of prothrombin time ≤1.8
  • Creatinine ≤1.9 mg/dL
  • Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test
  • Subjects are willing to sign an informed consent form

Who cannot take part

  • Patients with pre-irradiation of the breast
  • Patients undergoing immunosuppressive and/or systemic corticosteroid treatment
  • Acute infection disease
  • The presence of HIV, RW, HbsAg, HCV in the acute stage
  • Serious competing (somatic) diseases incompatible according to the researcher with brachytherapy
  • Mental illness
  • Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)
  • T4 category with skin involvement
  • Regional lymph node metastases
  • Ductal carcinoma in situ
  • Inflammatory breast carcinoma
  • Pregnancy or lactation
  • Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT
  • High probability of protocol non-compliance (in opinion of investigator)
  • Subjects not willing to sign an informed consent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for newly Diagnosed Breast Carcinoma patients with distant metastases

The group in the trial

  • DaRT SeedsTreatment being tested

    Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds

    Treatment: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases
Record updated
18 January 2024